Expression of mTOR signaling pathway markers in prostate cancer progression
- 1 May 2006
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 66 (11) , 1203-1212
- https://doi.org/10.1002/pros.20410
Abstract
BACKGROUND The PI3K/AKT/mTOR pathway is central to prostate cancer progression. A preliminary investigation of immuno-histochemical expression of mammalian target of rapamycin (mTOR) pathway markers was undertaken to identify patterns of expression in prostate tissue. METHODS Immunohistochemistry was performed on a custom-made prostate tissue array. Mean long scores and variability of long scores for each marker were recorded for normal lumenal cells, prostate intraepithelial neoplasia (PIN), and cancer. RESULTS Expression of PTEN decreased and mTOR signaling pathway markers increased in PIN and in cancer as compared to normal cells in the majority of samples. Overexpression of 4E-BP1 and p-4E-BP1 was observed in PIN and cancer. However, in cancer, the overexpression of 4E-BP1 was significantly higher than with any other marker. DISCUSSION Results suggest that 4E-BP1 overexpression is strongly associated with prostate cancer, especially when combined with PTEN and mTOR expression data. Hierarchical clustering analysis utilizing PTEN, mTOR, and 4E-BP1 separated normal from cancer cell populations in most cases. ProstateKeywords
This publication has 36 references indexed in Scilit:
- Molecular markers of prostate cancer outcomeEuropean Journal Of Cancer, 2005
- Inhibitors of the mammalian target of rapamycinExpert Opinion on Investigational Drugs, 2005
- USING MOLECULAR MARKERS TO PREDICT OUTCOMEJournal of Urology, 2004
- Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast CarcinomaClinical Cancer Research, 2004
- Detection of Prostate Cancer and Predicting ProgressionClinical Cancer Research, 2004
- Detection of Prostate Cancer Using Serum Proteomics Pattern in a Histologically Confirmed PopulationJournal of Urology, 2004
- Current strategies in the management of hormone refractory prostate cancerCancer Treatment Reviews, 2003
- Value of tissue markers p27kip1, MIB‐1, and CD44s for the pre‐operative prediction of tumour features in screen‐detected prostate cancerThe Journal of Pathology, 2002
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53Annals of Surgery, 2001